Genetic Immunity, a US clinical-stage biotechnology company, announced that it participated at the first Russian-Chinese HIV Congress in Moscow (Russia).
The company is focused on the discovery, development and commercialization of a new class of therapeutic vaccines for the treatment of chronic viral infections (HIV, HPV), cancer and allergies.
Peter Boros, Genetic Immunity`s President presented the pDNA-based platform technology and clinical trial data relating to HIV in front of an esteemed gathering of HIV experts. The DermaVir platform contains a novel plasmid DNA that encodes most HIV genes. The vaccine is administered topically using the DermaPrep medical device.
As part of the presentation, Genetic Immunity announced the launch of a Phase III clinical trial for the company’s lead product candidate, a therapeutic HIV vaccine, to be conducted at the Moscow City Center for the Prevention and Control of AIDS, with the planned enrollment of up to 200 patients.
Upon successful completion, Genetic Immunity plans to apply for marketing approval in the Commonwealth of Independent States (CIS) region.
Professor Alexey Mazus, Head of the Moscow City Center for the Prevention and Control of AIDS, commented:
“Mr. Boros gave an excellent presentation about Genetic Immunity’s therapeutic vaccine platform with a special emphasis on the company’s HIV results to date. I look forward to completing the planned Phase III trial, and – upon a successful result – to treating patients with a very promising new vaccine product.”